Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Total Non-Current Liabilities (2016 - 2025)

Viking Therapeutics' Total Non-Current Liabilities history spans 11 years, with the latest figure at $318000.0 for Q3 2025.

  • For Q3 2025, Total Non-Current Liabilities fell 57.88% year-over-year to $318000.0; the TTM value through Sep 2025 reached $318000.0, down 57.88%, while the annual FY2024 figure was $630000.0, 32.69% down from the prior year.
  • Total Non-Current Liabilities for Q3 2025 was $318000.0 at Viking Therapeutics, down from $410000.0 in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $1.5 million in Q1 2022 and bottomed at $318000.0 in Q3 2025.
  • The 4-year median for Total Non-Current Liabilities is $936000.0 (2023), against an average of $931266.7.
  • The largest annual shift saw Total Non-Current Liabilities dropped 20.74% in 2023 before it crashed 57.88% in 2025.
  • A 4-year view of Total Non-Current Liabilities shows it stood at $1.3 million in 2022, then fell by 25.71% to $936000.0 in 2023, then crashed by 32.69% to $630000.0 in 2024, then tumbled by 49.52% to $318000.0 in 2025.
  • Per Business Quant, the three most recent readings for VKTX's Total Non-Current Liabilities are $318000.0 (Q3 2025), $410000.0 (Q2 2025), and $502000.0 (Q1 2025).